e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

AN OVERVIEW ON PHARMACEUTICAL SOFTWARE

Bipasha Ray*1, Ahmed Azeem Khan*2, Adiba Rahman*3, Sapna Yadav*4, Dr. Anil Kumar*5, Krishanu Samanta*6

*1,3,4Research Scholar, Pharmacy College, Itaura, Chandeshwar, Azamgarh, U.P. India.

*2,6Associate Professor, Pharmacy College, Itaura, Chandeshwar, Azamgarh, U.P. India.

*5Professor, Pharmacy College, Itaura, Chandeshwar, Azamgarh, U.P. India.

Corresponding Author: Bipasha Ray

DOI : https://www.doi.org/10.56726/IRJMETS47081

ABSTRACT

As the pharmaceutical industry is growing rapidly, it is important to see the different aspects and considered on it. New innovations are needed and more than that solve the scientific problems related to pharmaceutical industries production, documentation, cGMP practices, and other regulatory bodies. Now a day's computer program are more suitable to monitoring and maintaining pharmaceutical records. To fulfil the regulatory bodies requirements pharmaceutical software are been installed. In this article, the overview on software and its importance and need is covered.

Keywords: Pharmaceutical Software, Artificial Intelligence, Drug Design.

I. INTRODUCTION

Software has evolved into a critical tool for the pharmaceutical industry, aiding data administration, process optimisation, and regulatory compliance. Quality is achieved by the use of development methodologies and Verification and Validation (V&V) protocols throughout the development process (Mannam & Mubeen, 2018). Computer software may assist in relieving medical professionals of daily documentation and other clerical duties, reducing errors and increasing accuracy in data transmission and storage, and reducing the use of animals and chemicals, improving productivity and providing solutions for time-consuming manual tasks, developing uniform standards and continuing monitoring or transactions, and providing fast and direct access to various information sources via remotely located terminals (Mali, 2022).It's no longer enough to excel some of the time for your development projects in the internet era, where software is more mission important than ever. You must constantly offer exceptional software efficiency and do so faster than ever before (Upadhyay, 2012). Significant progress has been achieved in implementing new methodologies to enhance our understanding of processes and products in a variety of manufacturing sectors and associated industrial sciences. However, in recent decades, there has been a growing concern in the pharmaceutical business about improving medicine safety and quality while simultaneously lowering production costs. This involves the implementation of better organised pharmaceutical development and manufacturing techniques. (R & K, 2015).

II. AN OVERVIEW- PHARMA SOFTWARE

Automated system

A system that incorporates data input, computer processing, and information output for either reporting or automated control. Used to refer to a regulated pattern of interacting activities and procedures that come together to generate organised wholes. (Hoffmann A, 1998).

Digitalization in pharmaceutical industry

The digitization of any industrial industry is a critical step in improving the production process. This digitalization includes growing use of robots, automation solutions, and computerization, resulting in cost savings, increased efficiency, increased productivity, and responsiveness to change. However, the pharmaceutical industry (PI) has been resistant to digitization, owing to its long experience and the complex nature of the development and manufacturing procedures involved. Nonetheless, due to the ever-increasing need for both classic and new medications, there is a strong need to digitalize the PI sector. In this digitization process, Contract Development and Manufacturing Organisations (CDMOs) have a unique problem.

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

Digitalization of the PI, especially inside CDMOs, should be tightly aligned with the key concepts of Good Manufacturing Practise (GMP) to accomplish. (Hole, Hole, & McFalone-Shaw, 2021)

Compliance Criteria for Computerized System Validation

The FDA studied 3,140 medical device recalls from 1992 to 1998 and discovered 242 programme flaws, 192 of which were tied to post-improvement software issues. To address these concerns, the study emphasises rigorous system testing and quality-focused software engineering. Computer validation is required by the Federal Register (October 7, 1996; effective June 1, 1997) to provide system quality control. Software validation is critical in medical devices, as it plays an important role in ensuring the quality of healthcare products.

Classification of Software in Pharmaceutical Industry:



TYPES OF SOFTWARES USED IN MANUFACTURING

In the field of pharmaceutical different categories of software are used for different purposes.

Electronic Data Capture (EDC): It refers to software used in clinical research to collect and manage electronic data from clinical trials. Its major goal is to replace traditional paper-based data collection methods, which are notorious for being time-consuming and error-prone. EDC software is designed to collect data directly from clinical trial participants and securely store it in an organised manner. This programme enables researchers to collect, oversee, and monitor data in real time, thereby improving efficiency and speeding up clinical trial outcomes. EDC software is essential for gathering, maintaining, and analysing clinical trial data. For streamlined operations, it frequently combines with Clinical Trial Management Systems (CTMS) and Clinical Data Management Systems (CDMS). Some of the EDC software are- *Oracle Health Sciences Clinical, Medidata CTMS, BioClinica CTMS, BioClinica CTMS, Veeva Vault CTMS (cloud-based software), Clinical Conductor CTMS.*

Electronic Document Management Systems (EDMS): EDMS (Electronic Document Management System) software is used to handle and maintain electronic documents connected to medication development and production, such as standard operating procedures (SOPs), regulatory submissions, and other relevant papers. Among the most common EDMS software solutions used in the pharmaceutical business are- *Veeva Vault, Documentum, OpenText, SharePoint, MasterControl.*

Pharmacovigilance Software: Pharmacovigilance software is used to track and monitor ADRs and other safety-related information. Pharmacovigilance is a subset of clinical trials, classified as Phase IV or postmarketing surveillance. In the field of medication safety, pharmacovigilance software is used to manage

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

adverse events and report potential safety issues with pharmaceutical goods. Pharmacovigilance software examples include: *Oracle Argus, ArisGlobal Safety, VigiFlow, AB Cube, PVWorks.*

When selecting pharmacovigilance software, take into account factors like the magnitude and intricacy of the pharmacovigilance system, the precise functionalities needed, and the financial plan.

Enterprise Resource Planning (ERP) Systems: Enterprise Resource Planning (ERP) software is used to manage corporate procedures and operations, including duties such as inventory management, supply chain management, and financial operations. Among the most often used ERP solutions in the pharmaceutical industry are: *SAP, Oracle ERP, Microsoft Dynamics, Infor ERP, Epicor ERP.*

Computer-Aided Design (CAD) Software: Computer-Aided Design (CAD) software is used to create medication delivery systems such as inhalers, injectors, and transdermal patches. CADD, or Computer-Aided Drug Design, is a method that uses computer software to create and refine novel medicines or to improve current drug molecules. CADD examines and simulates the interactions between pharmacological molecules and biological targets such as proteins or enzymes using a variety of computer approaches. The goal of CADD is to identify potential pharmacological choices with enhanced properties such as increased potency, selectivity, and bioavailability while minimising adverse responses and toxicity. Some of examples of CADD software are- *Schrödinger, MOE (Molecular Operating Environment), Discovery Studio, Open Eye, Accelrys.*

Manufacturing Execution Systems (MES): MES (Manufacturing Execution Systems) software is used during the manufacturing cycle for batch processing, equipment supervision, and quality assurance. These are computer-based systems used in manufacturing to monitor and control the production process. MES software often provides real-time data collection, analysis, and administration of manufacturing activities, assisting manufacturers in increasing efficiency, reducing inefficiencies, and increasing profitability. MES spftware are *Siemens Opcenter, SAP Manufacturing Execution, Wonderware MES, ABB Ability Manufacturing Operations Management, Rockwell Automation Factory Talk Production Centre.*

Quality Management Systems (QMS): Quality Management System (QMS) software is used to monitor and manage the quality of pharmaceutical products throughout their full life cycle. This involves activities like document supervision, dealing deviations and non-conformances, and managing change. Within the pharmaceutical industry, there are numerous possibilities for Quality Management System (QMS) software, some of which are as follows: *Master Control*, *EtQ Reliance, SAP QM, AssurX, Pilgrim Quality Solutions.*

Regulatory Information Management (RIM): Regulatory submissions to regulating organisations like the FDA are managed and filed with the help of Regulatory Information Management (RIM) software. This includes tasks like product registration, clinical trial application filing, and electronic regulatory document submission. Among the most extensively used RIM systems in the pharmaceutical sector are: *ArisGlobal RIMS, Veeva Vault, RIM, ISI Regulatory Suite, Samarind RMS, Lorenz Docubridge.*

Electronic Trial Master File (eTMF) software: Electronic Trial Master File (eTMF) software is a form of software used in the pharmaceutical industry to manage clinical trial documentation. The electronic study Master File (eTMF) is a digital adaption of the traditional paper-based Trial Master File (TMF), which contains critical documents generated or gathered during a clinical study. Among the most commonly used eTMF software solutions are:*Master Control, eTMF, SureClinical eTMF, Phlexglobal PhlexEviewe, TMF Connect.*

Statistical Analysis Software: Statistical analysis software is used to assess and comprehend data collected from preclinical and clinical research undertaken during trials. This software is critical in the pharmaceutical industry since it allows for the analysis and interpretation of complex data gathered throughout the drug development process. It enables researchers and statisticians to identify trends, patterns, and correlations in data, allowing for informed decision-making based on the results. Among the most often used statistical analysis software alternatives in the pharmaceutical business are: *SAS (Statistical Analysis System), SPSS (Statistical Package for the Social Sciences), STATA is statistical analysis software, MedCalc.*

Simulation Software: Simulation software is used in the pharmaceutical industry to reproduce and simulate the behaviours of pharmaceutical products and manufacturing methods. This practise aids in the detection of prospective problems and the refinement of the manufacturing process. Simulation software has numerous uses in the pharmaceutical sector, including drug discovery, pharmacokinetic modelling, clinical trial design,

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

and process optimisation. Among the most commonly used simulation software alternatives in the pharmaceutical industry are: *GastroPlus, Simcyp, Arena, ADAPT (Advanced DoseResponse Analysis Prediction Tool), Virtual Cell, MATLAB.*

Sales and Marketing Software: Customer Relationship Management (CRM), sales projection, and market analysis are just a few of the sales and marketing responsibilities that sales and marketing software manages. *Veeva CRM is a customer relationship management, Salesforce Health Cloud, Marketo, Adobe Experience Manager, SAP Sales Cloud, QlikView.*

Data Analytics and Business Intelligence (BI) Software: Clinical trial data and sales figures are only two examples of large datasets that may be examined and comprehended using data analytics and Business Intelligence (BI) software. This aids in the discovery of trends and patterns, which aids in the direction of commercial strategy. Data analytics and BI software are critical in the pharmaceutical industry for analysing large amounts of data and offering insights into the efficiency of various business operations. Several common examples of data analytics and business intelligence tools widely used in the pharmaceutical sector include*: Tableau, SAP Business Objects, SAS, IBM Congo's Analytics, Microsoft Power BI, and Oracle Business Intelligence.*

Electronic Health Records (EHR) Software: EHR (Electronic Health Record) software is utilized to maintain comprehensive patient health records, encompassing medical histories, test results, and medication histories. In the pharmaceutical industry, EHR software can also be employed to manage patient data associated with clinical trials, drug safety, and pharmacovigilance. These platforms facilitate the digital storage and efficient management of patient health data, contributing to improved patient care and pharmaceutical operations. Some examples of EHR software commonly used in the pharmaceutical industry include OpenClinica, Epic, Cerner, Care Cloud, and Athena health.

Manufacturing Process Management (MPM) Software: Manufacturing Process Management (MPM) software is critical in the pharmaceutical sector for controlling and organising various stages of manufacturing, from raw material acquisition to final product distribution. The following are some examples of MPM software that is commonly used in the pharmaceutical industry: *SAP Manufacturing Execution, Camstar Medical Device Suite, Master Control Manufacturing Excellence, Apriso Manufacturing Execution System, Werum PAS.* (Joshi & Salunkhe, 2020)

Preparation of formulation through pharmaceutical software

To address the inadequacies discovered in the usual formulation method, a novel strategy was devised, which included the use of Experimental Design, which is recognised as an optimisation technique. Optimisation becomes necessary during the formulation process to discover the most favourable formula, extracting insights from the prepared product's assessment data. In some cases, optimisation can be described as a method for achieving the most advantageous combination of product or process attributes. It also entails picking the best material or substance from a variety of possibilities (BS, R, & N, 2008). Expert design is used in the creation of drug delivery systems such as extended-release tablets and targeted delivery mechanisms such as liposomes, ethosomes, and nanoparticles, as well as traditional prescription formulations such as tablets and capsules. Its application extends beyond the pharmaceutical business. Design Expert, for example, is a critical tool for studying the ideal composition of vegetable oil mixtures as raw materials for biodiesel synthesis (Ramadhani, Riyadi, Triwibowo, & Kusumaningtyas, 2017). The terms "Formulation" and "Design Expert" produced 63 articles, 51 of which matched the inclusion requirements. The criteria for inclusion in this review article are journals that published research on formulation and optimisation, specifically using the software Design Expert, between 2011 and April 2020.

III. DESIGN EXPERT

State Ease created Design Expert, a statistical software application. Its principal function, since its inception in 1996, has been to facilitate experimental designs, notably in establishing the most effective formulation for a preparation. This software, in addition to assisting in optimisation, analyses the components involved in the experiment. It is divided into three study avenues within the programme, each geared to a distinct form of experimental design: *screening, characterization, and optimisation options*.

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

Screening requires the fewest experimental runs but yields restricted results. The "run" specifies the number of trials to be carried out based on the experimental design specified. This method is used when there are multiple potential factors present, but their real impact is unknown. It assists in the identification of numerous relevant components by using only two levels for each factor and finding major effects (without interactions). However, additional research via a second Design of Experiment (DOE) is required to estimate interactions and go deeper into the needs. Characterization necessitates a bigger number of experimental runs per factor, which provides more information. It is used when working with a small number of variables. The primary goal is to determine which factors have a substantial influence on the response, as well as their interactions, by fitting a two-factor interaction model. Optimisation necessitates the most runs per element while providing the most comprehensive information. It enters the picture after narrowing down the list of known critical components and focusing on their optimal potential inside the test area. This method seeks to uncover factor settings that maximise or minimise response. There are three Design of Experiments options, each with three methods: factorial/response surface, mixture, and combined, each with different tactics for attaining optimisation goals.

1. **Factorial Design** The use of regression equations to describe the correlation between the response variable and one or more independent variables is referred to as factororial design. It is one of the most used design types for process improvement. Factorials are used in research to investigate the impact of various circumstances on study outcomes and to find potential relationships between them. Factors, levels, and effects are three fundamental components of the factorial design framework. Factors describe the magnitude of the independent variable that determines the subsequent output or dependent variable. These elements are classified as quantitative (numerical factors such as 1% or 2% concentrations) and qualitative (non-numerical criteria such as quality qualities or polymer type). Levels are the specific values or constants that are connected with a factor. Changes in the environment are represented by effects (S & C., 2004).
2. **Central composite design (CCD)** Because both the optimisation procedure and the optimal location are unknown in the area of Response Surface Methodology (RSM), the central composite design is used within the optimisation process to determine an approximate optimal path., CCD is rotatable, or at point x, which is the same distance away. There are several models available in the Central Composite Design (CCD), including mean, linear, quadratic, 2FI (2nd order main effects), and cubic models. The criteria used to select the response model are similar to those used to select models inside mixture designs. The outcome of the desirability value is used to determine the ideal point. Desirability denotes the level of fulfilment or near to the ideal point. A desirability value close to one reflects the expected or desired outcome (Montgomery, 2019).
3. **Box-Bhenken design (BBD)** For optimisation assignments involving three independent variables, the Box-Behnken Design (BBD) is used. The Difference Box-Behnken Design is regarded more efficient than the Central Composite Design (CCD) since it uses fewer experimental runs or units. Despite the fact that it has fewer runs, the Box-Behnken Design has high predictive skills for both linear and quadratic models, allowing for precise determination of the optimum value (Perincek & Colak, 2013) (I, R, & IS, 2022).
4. **Mixture design** Mixture designs are used to describe components in a formulation that alter in proportion to one another. Individual variable proportions within the mixture are continually adjusted to preserve a set overall value, such as 100 percent by weight. This methodology is still usable with a small number of variable components, demonstrating increased responsiveness to these compounds. Mixture Design makes it easier to derive optimal formulas by using response data derived from specific preparation parameters. Among the different formulations produced by various mix modifications, the optimal formula is one that produces assessment results that fall within the prescribed limit range for each parameter.
5. **Combined** The Combined or Combination design of experiment (DOE) combines elements of factorial/RSM and mixture designs. It is used to investigate the link between variable compositions and process variables within the confines of a single DOE (Design of Experiment).

The drug delivery system

Design Expert software is used for more than just traditional dose formulations including tablets, capsules, and emulsions. Numerous research have been conducted to investigate the development of medication delivery systems aided by Design Expert software.

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

Percent prediction error

The percent prediction error is a statistic used to assess an analytical method's prediction accuracy. An acceptable forecast error value is usually less than 4%. The prediction error value for the dependent variable in this case ranges between 2% and 3.5%, suggesting that it still fits the criteria and proving the method's applicability for analysing the completed study. (Usman, Ejaz, & Safdar, 2018)

MARKET SHARES OF PHARMACEUTICAL SOFTWARE

The global market for pharmaceutical quality management software is expected to reach USD 1.5 billion in 2022, with a compound annual growth rate (CAGR) of 12.58% from 2023 to 2030. Increased digital technology integration, the critical need for regulatory compliance, and the expanding complexities within pharmaceutical supply chains are driving market expansion. Increased drug manufacturing expenses and the industry's increasing use of technology also contribute considerably to market expansion. For example, the Congressional Budget Office said in 2021 that the costs of developing a new drug, including initial investments and unsuccessful drug prices, can range from less than USD 1 billion to more than USD 2 billion.

Graphical representation of market share of pharmaceutical management software market:

(Pharmaceutical Quality Management Software Market Size, Share & Trends Analysis Report By Application (Data Management, Risk Management), By Deployment Mode (Cloud & Web-based, On-premise), By Region, And Segment Forecasts, 2023 - 2030, 2018 - 2021).

Pharmaceutical Quality Management Software Market Report Scope:

Report Attribute	Details
The market size value in 2023	USD 1.7 billion
The revenue forecast in 2030	USD 3.9 billion
Growth rate	CAGR of 12.58 % from 2023 to 2030
The base year for estimation	2022

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

Historical data	2018 - 2021
Forecast period	2023 - 2030
Quantitative units	Revenue in USD million/billion and CAGR from 2023 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Application, deployment mode, region
Regional Scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; UK; Germany; France; Italy; Spain; Sweden; Norway; Denmark; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled	MasterControl Solutions, Inc.; AmpleLogic; Qualio; Pilgrim (IQVIA); QT9; Sparta Systems (TrackWise); AssurX, Inc.; Dassault Systèmes; ETQ, LLC (Hexagon); Veeva Systems; Qualityze Inc.; Ideagen
Customization scope	Free report customization (equivalent to up to 8 analyst's working days) with purchase. Addition or alteration to country, regional, and segment scope
Pricing and purchase options	Avail of customized purchase options to meet your exact research needs.

IV. ARTIFICIAL INTELLIGENCE

The pharmaceutical industry is a critical sector that is critical in saving lives. Its operations concentrate upon constant innovation and the adoption of new technology to meet global healthcare challenges and medical crises such as the recent epidemic (Krikorian & Torreele, 2021). In the pharmaceutical industry, innovation is frequently based on extensive research and development across multiple domains, including production technology, packaging concerns, and customer-centric marketing techniques, among others (Chavda, Vihol, Patel, & Redwan, 2023). Pharmaceutical innovations range from small medicinal molecules to biologics, with an emphasis on improved stability and potency to answer unmet medical requirements. Evaluating the large toxicity levels associated with these innovative medications remains a major worry, necessitating extensive research and inquiry in the coming years. The ultimate goal is to introduce pharmacological compounds that provide optimal advantages while also being suitable for incorporation into the healthcare system. However, the pharmaceutical business faces significant obstacles that will necessitate greater advancement through technology-driven initiatives in order to meet global medical and healthcare demands (Scannell, Blanckley, Boldon, & Warrington, 2012) (Munos, 2009) (Mak & Pichika, 2018).

CURRENT PHARMACEUTICAL CHALLENGES AND THE ROLE OF AI

Aside from treating rare diseases, many new small compounds face generic competition, necessitating substantial data and clinical trials for their commercialization. These processes increase economic constraints on businesses, encouraging them to pursue additional innovation. However, the bimolecular drug sector is

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

rapidly expanding to meet the constraints provided by the limited scale and dispersion of small-molecule research and innovation. Small molecules' actions are determined by their shape and reactivity. (Dickherber, Morris, & Grodzinski, 2015) (NNI Budget Supplements and Strategic Plans) (Colombo, Beck-Broichsitter, Bøtker, Malmsten, Rantanen, & Bohr, 2018) (Troiano, Nolan, Parsons, Hoven, & Zale, 2016) (Puri, Pathak, Sutariya, Tipparaju, & Moreno, 2015) (Vyas, Thakur, Riyaz, Bansal, Tomar, & Mishra, 2018) (Hassanzadeh, Atyabi, & Dinarvand, 2019)

While AI has enormous potential for medication delivery innovation and discovery, it has severe limitations that require human interaction to comprehend complex data. AI predictions rely largely on datasets, but the interpretation phase, which is typified by uncertain outcomes, frequently necessitates human intervention to reach appropriate conclusions. Algorithm bias is a common topic in AI systems, influencing information processing for predictions and hypothesis testing. Furthermore, docking simulations typically result in the discovery of inactive molecules, which is a regular occurrence (Cerón-Carrasco, 2022). The learning process is divided into two parts: supervised and unsupervised learning, with the choice of algorithm being crucial. Unsupervised learning deals with uncertain outputs while supervised learning works with known inputs (features). Predictions of output, such as labels or targets, are formed using numerous inputs or features in supervised learning. Unsupervised categorization, on the other hand, attempts to create homogeneous groupings based on shared traits. (Sarker, Machine Learning: Algorithms, Real-World Applications and Research Directions, 2021)

Supervised AI Learning

Supervised learning is a sort of machine learning in which an algorithm is trained on a labelled dataset with the expected output already known. This method is used in a variety of domains, including image identification, natural language processing, and predictive modelling. It uses labelled data to train algorithms for tasks such as data categorization and outcome prediction. The basic tasks in supervised learning are classification (predicting a label) and regression (predicting a quantity). (Sarker, 2022)

1. **Drug Discovery and Design:** Supervised learning systems can predict the activity or characteristics of potential medication candidates. The model learns patterns and connections between molecular properties and anticipated results by training on a collection of known substances and their corresponding activities. This skill makes it easier to predict the activity, effectiveness, or undesirable effects of novel compounds, assisting in the drug development and design process. (Dara, Dhamercherla, Jadav, Babu, & Ahsan, 2022)
2. **Predictive Maintenance and Quality Control:** Supervised learning is useful in pharmaceutical manufacturing for predictive maintenance and quality control applications. The model learns to predict equipment breakdowns, variations in product quality, and abnormalities in the manufacturing process by training on datasets collected from manufacturing processes, equipment sensor readings, or quality assessment outcomes. This skill provides proactive maintenance methods and comprehensive quality assurance standards. (Kavasidis, Lallas, Gerogiannis, & Charitou, 2023)
3. **Drug Target Identification:** Through the examination of biological data, supervised learning approaches can help find prospective therapeutic targets. The model discerns patterns and discovers prospective targets by training on datasets including information about genetic, proteomic or transcriptomic features and their correlation with treatment response or illness progression. (Bagherian, Sabeti, Wang, Sartor, Nikolovska-Coleska, & Najarian, 2021)
4. **Disease Diagnosis and Prognosis:** Using medical data, supervised learning algorithms can be used to diagnose diseases or predict patient outcomes. The model learns to categorise individuals into separate disease groups and forecast illness progression or response to treatment by training on labelled datasets containing patient characteristics, clinical information, and disease outcomes. (Kumar, Koul, Singla, & Ijaz, 2023)
5. **Adverse Event Detection**: Supervised learning algorithms can be used to detect and classify adverse medication occurrences in pharmacovigilance data. The model discerns trends and finds potential safety indicators by training on labelled adverse event data, facilitating in the identification and delineation of adverse occurrences. (Chapman, Peterson, Alba, DuVall, & Patterson, 2019)
6. **Predictive Modeling for Clinical Trials:** Supervised learning approaches are useful in projecting clinical trial outcomes. The model learns to predict patient response, treatment effectiveness, or safety outcomes by

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

training on historical clinical trial data that includes patient features, treatment techniques, and trial results. This knowledge can be used to improve trial design and patient selection procedures. (Elkin & Zhu, 2021)

UNSUPERVISED AI LEARNING

Unsupervised learning in machine learning refers to algorithms that operate without the use of labelled data. Instead, they are interested in self-identifying patterns and connections in data. This method is useful for exploratory data analysis, revealing hidden structures or clusters within datasets. Its goal, dubbed "data-driven methodology," is to uncover patterns, structures, or insights from unlabeled data. Clustering, dimensionality reduction, visualisation, establishing association rules, and anomaly detection are all examples of frequent unsupervised learning tasks. Various techniques are used to address these tasks, including clustering algorithms (e.g., hierarchical clustering, K-means, K-medoids, single linkage, complete linkage, BOTS), association learning algorithms, and feature selection and extraction techniques (e.g., Pearson correlation, principal component analysis). 4445As detailed below, unsupervised learning approaches in AI might be useful for pharmaceutical applications, notably for exploratory analysis, pattern identification, and data visualisation:

1. **Clustering:** Clustering techniques enable the detection of intrinsic groupings or clusters within data by grouping data points based on similarities. Clustering is used in pharmaceutical settings to reveal subsets with similar characteristics from varied datasets like as gene expression profiles, chemical structures, or patient information. This approach aids in the identification of targets, the categorization of patients, and the identification of discrete categories among chemicals or disorders. (Karim, et al., 2021)
2. **Dimensionality Reduction:** Dimensionality reduction techniques such as principal component analysis (PCA) and t-distributed stochastic neighbour embedding (t-SNE) are used to simplify high-dimensional datasets while keeping crucial information. These approaches aid in the visualisation and exploration of complex datasets, the identification of key variables or features, and the facilitation of decision-making procedures. Dimensionality reduction approaches are useful for a variety of pharmaceutical data types, such as gene expression data, drug activity profiles, and imaging data. (Vamathevan, et al., 2019)
3. **Anomaly Detection:** Anomaly detection algorithms are experts at spotting unusual or anomalous data points that deviate significantly from expected patterns. Anomaly detection is useful in the pharmaceutical industry for detecting adverse events, identifying potential safety issues, and disclosing data integrity issues. Unsupervised anomaly detection approaches such as the local outlier factor (LOF) or isolation forest are useful in identifying unexpected patterns or data sets that merit further investigation. (Goldstein & Uchida, 2016)
4. **Association Rule Mining:** Association rule mining approaches, such as the Apriori algorithm, are concerned with revealing significant links or correlations between elements in a collection. Association rule mining is useful in pharmaceutical applications for analysing drug-drug interactions, adverse event records, and co-occurrence patterns among medical disorders and pharmaceuticals. These methods provide insights into probable drug interactions, identify medication trends, and support pharmacovigilance efforts. (Noguchi, et al., 2018)
5. **Topic Modeling:** Topic modelling algorithms, such as latent Dirichlet allocation (LDA), find hidden topics or themes in large text datasets. Topic modelling is useful in pharmaceutical contexts for analysing scientific literature, clinical trial data, or social media information to identify primary research themes, rising trends, or patient attitudes. This method aids in literature analysis, competitive intelligence, and understanding patient views. (Liu, Tang, Dong, Yao, & Zhou, 2016) (Zhao, et al., S8 (2015))

AI FOR DRUG DISCOVERY

AI has transformed medication research and development in several ways. Among the most important contributions of AI in this subject are the following:

Target Identification: AI systems may examine diverse data types, including genomic, proteomic, and clinical data, to identify possible treatment targets. AI assists in the development of drugs capable of controlling biological mechanisms by uncovering disease-linked targets and molecular pathways.

Virtual Screening: AI enables the rapid screening of large chemical repositories to identify new drug candidates with a high likelihood of binding to specific targets. AI assists researchers in prioritising and

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

selecting compounds for experimental evaluation by simulating chemical interactions and anticipating binding strengths, resulting in time and resource savings.

Structure-Activity Relationship (SAR) Modeling: AI models can correlate the chemical structure of substances with their biological activity. This allows researchers to refine therapeutic candidates by creating molecules with desired properties such as increased potency, selectivity, and favourable pharmacokinetic properties.

De Novo Drug Design: AI algorithms can suggest unique chemical compounds similar to pharmaceuticals by using reinforcement learning and generative models. AI broadens the chemical landscape by integrating knowledge from chemical repositories and experimental data, helping the development of novel therapeutic candidates.

Optimization of Drug Candidates: AI algorithms can analyse and improve medication candidates by weighing many criteria such as efficacy, safety, and pharmacokinetics. This helps researchers refine medicinal compounds to increase efficacy while minimising side effects.

Drug Repurposing: AI techniques can search large biomedical datasets for licenced medications with potential therapeutic applications for a variety of disorders. AI accelerates the drug discovery process and reduces costs by repurposing current medications for new indications.

Toxicity Prediction: AI systems can predict drug toxicity by analysing the chemical composition and properties of substances. Machine learning algorithms trained on toxicology databases can predict negative effects and identify hazardous structural features. This helps researchers prioritise safer chemical compounds and reduce potential bad effects during clinical studies.

AI-powered drug research and development approaches have the potential to accelerate the discovery, optimisation, and creation of novel therapeutic candidates. This has the potential to improve pharmaceutical efficiency and efficacy. (Shah, Chavda, & Soniwala, 2023)

AI TOOL APPLICATION IN DOSAGE FORM DESIGNS

AI could provide an automated system that can be applied to all of these procedures for more precise estimation and increased data refinement, resulting in continuous improvement. AI provides benefits by gathering data from many sources and providing suggestions for the chosen drug delivery mechanism to perform as planned. Analysing molecular information, patient records, and pharmacokinetic data is a complex data assessment that could lead to the identification of the best active medication for treating patient diseases or needs. AI is useful in the drug discovery process as well as drug repurposing strategies. This entails adapting established therapies to new ailments. Patient requirements and illness state have a substantial impact on formulation, pharmacokinetics, and drug development. AI solutions enable the management and analysis of large amounts of data, allowing for a better strategy for the logical design of the product. This modern computational model is used to investigate the pharmacokinetic characteristics of the medication delivery system. The dependability of preclinical models is a crucial difficulty in the pharmaceutical industry's research and development. The dependability is dependent on the parameters specified, and this extends to complicated in-silico models. These cases are linked to drug interactions involving membranes and might be examined more thoroughly in the simulated environment. (Balogh, Müller, & Könczöl, 2013)

AI for Drug Delivery

The convergence of AI and big data in the pharmaceutical industry has given rise to computational pharmaceutics, which tries to improve drug delivery mechanisms through the use of multiscale modelling strategies. Computational pharmaceutics examines large datasets and predicts drug behaviour using AI algorithms and machine learning methodologies. Improve drug delivery methods without depending on significant trial-and-error experiments. This shortens the medication development timeframe, reduces costs, and increases efficiency. AI algorithms may evaluate detailed links between pharmacological properties, formulation factors, and physiological parameters, forecasting drug behaviour across several dimensions. They aid in anticipating the drug's physicochemical properties, in vitro release pattern, and stability. Using appropriate AI technologies allows researchers to uncover potential dangers and roadblocks associated with drug delivery systems at an early stage of development. This enables proactive changes and adjustments to

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

reduce hazards and improve drug efficiency. The use of AI and computational modelling reduces the reliance on time-consuming and costly trial-and-error trials, lowering the possibility of unexpected findings. (Lou, Lian, & Hageman, 2021)

AI Application for Parenteral, Transdermal and Mucosal Route Products

AI can be used to generate and manufacture injectables, biologics, and other complex formulations. AI systems that forecast complex medication formulation physicochemical characteristics can help with formulation advancement. By evaluating formulation elements, additives, and manufacturing procedures, AI models improve pH, solubility, stability, and viscosity. This aids in the development of reliable parenteral formulations. AI has the potential to streamline parenteral product production while ensuring quality, efficacy, and minimising variability. Through the study of real-time process data, AI algorithms can detect process components that influence product qualities and recommend appropriate improvements. As a result, product homogeneity improves, batch failures are decreased, and manufacturing efficiency improves. By analysing process data and product attributes, AI algorithms may measure adherence, identify potential noncompliance issues, and recommend process improvement solutions. This promotes compliance with GMP and regulatory standards (Mohan, Kamaraj, & Navyaja, 2022). The availability and promise of cutting-edge machine learning (ML) technology in pharmaceutical and materials science. They show how machine learning (ML) can speed up the development of novel drug delivery methods by properly predicting in vitro drug release from long-acting injectables (LAIs). The study emphasises the interpretability of machine learning models, which can provide insights into decision-making. The classic trial-and-error strategy used in the development of ocular, transdermal, pulmonary, and other mucosal drug delivery systems lacks full insight, making it useless for complex formulations. In silico modelling and simulations have significant advantages in that they provide full insights and allow for a rational approach to formulation creation. Incorporating in silico methodologies, overcoming data challenges, and promoting interdisciplinary collaborations can lead to more effective and purpose-driven drug formulation design in the pharmaceutical industry. (Daka & Peer, 2012) (Turchin, Masharsky, & Zitnik, 2023) (Das, Preuss, & Mazumder, 2016)

V. LIMITATIONS OF AI TOOLS

AI-driven models have a number of constraints, including the need for large datasets, potential biases, and limited interpretability. As a result, it is prudent to supplement AI-based models with traditional experimental procedures to ensure drug safety and efficacy. Some of the constraints are listed below:

Lack of Transparency: The lack of openness can make obtaining regulatory approval for AI-based drug development tools more difficult, as it can be difficult to demonstrate the model's precision and dependability in predictions. Furthermore, a lack of transparency might diminish faith in the model's predictions, particularly when these projections contradict doctors' or researchers' expectations. (Kiseleva, Kotzinos, & Hert, 2022) (Kelly, Karthikesalingam, Suleyman, Corrado, & King, 2019)

Limited Availability of Data: AI algorithms rely on large amounts of data to make accurate predictions. However, in other cases, data availability for a specific medicine or population may be limited, leading in less precise predictions or biassed outcomes. Rare diseases, for example, frequently have minimal data available, creating a significant barrier in developing AI models.

Biases in Data: The quality of the data utilised to train AI models determines their usefulness and accuracy. When data exhibits bias or incompleteness, the resulting predictions may similarly be biased. In the discipline of pharmacology, the consistency of patient cohorts in clinical trials is a significant issue.**21819** Deploying an AI model to support healthcare decision-making can be a significant challenge. As a result, it's critical to guarantee that the training data used to build AI models appropriately represents the population to which the model will be applied. Furthermore, the data must be trustworthy, complete, and unbiased.

Inability to Incorporate New Data: After an AI model has been trained, adding new data or upgrading the model might be difficult. This constraint can have a substantial impact on drug development methods, especially when fresh information and data are constantly emerging. For example, the release of new pharmaceuticals or the creation of more data from clinical trials may necessitate the need to update an AI

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

model to account for this new knowledge. Nonetheless, updating an AI model can be difficult, requiring significant time and resources to retrain the model with new data.

Limited Ability to Account for Variability: AI models are generally trained on large datasets, which may demonstrate bias towards the data's typical responses. As a result, these models may struggle to accurately predict medication responses for individuals who differ significantly from the average reaction. This is especially concerning for drugs that elicit a wide range of responses in different people, such as those used to treat cancer, where the variability might be significant. (Thomas, Abraham, Baldwin, Piplani, & Petrovsky, 2021)

Interpretation of Results: Even for domain specialists, AI models can be complex and produce outputs that are difficult to comprehend. These models may struggle to provide a clear explanation of their decision-making process, making it difficult for physicians and researchers to understand and evaluate the results. Occasionally, the data may be challenging to translate into useful insights for clinical practise or medication development.

Ethical Considerations: Ethical considerations are critical in the use of these technologies in medication development. Given that sensitive health data is commonly used as the foundation for training AI models, patient privacy is a major problem. Prioritising data safety and security are critical issues that must be prioritised and cannot be overlooked. It is critical to ensure that patient data is collected and used in a way that protects their privacy and rights.

Complex biological systems: The ability of AI to exactly mimic the complexity of complete biological systems is limited. Biological systems are complex and dynamic, with many interconnected pathways, feedback loops, and complex chemical interactions. This complexity poses challenges for AI models, which commonly streamline and simplify core biological operations. (Eslami, et al., 2022)

Lack of Clinical Expertise: Although AI is excellent at detecting correlations, it is critical to recognise that individual patient therapies may vary despite these relationships. AI algorithms typically operate within a statistical framework, which may limit their comprehension of complex elements and the major influence that specific parameters might have. The complex environment, in which treatment decisions are impacted by several personalised elements, offers a challenge for AI models that are predominantly based on statistical connections. (Davenport & Kalakota, 2019)

Inactive Molecules: Through the use of algorithms and scoring functions, AI employs a computational methodology to forecast the binding interactions between a tiny chemical and a target protein. These simulations may, however, infrequently identify inactive compounds. Given that docking algorithms only explore a limited range of conformations, one key challenge is accurately depicting the conformational flexibility of both the small molecule and the target protein. This limitation may result in inaccurate evaluations of binding affinities, resulting in false-positive or false-negative results. (Cerón-Carrasco, ChemMedChem, 2022)

EMERGING AI TRENDS IN PHARMACEUTICALS

The prevalent trends demonstrate AI's broad influence in pharmaceuticals, including drug discovery, personalised medicine, formulation enhancement, clinical trial protocols, safety vigilance, and supply chain management. Here are a few notable trends:

1. Drug Discovery and Development: AI is revolutionising drug discovery by enabling virtual screening, molecular modelling, and anticipatory analytics.
2. Precision Medicine: AI is being used to improve precision medical strategies. AI algorithms may distinguish subgroups among patients, forecast reactions to therapies, and aid in making personalised treatment decisions by examining patient data that includes genomes, proteomics, and clinical documentation.
3. Drug Repurposing: AI is being used to uncover new applications for existing medications, a process known as drug repositioning or repurposing.
4. Drug Formulation and Delivery: AI helps to improve medicine formulations and delivery systems. AI models can estimate drug release kinetics and absorption patterns while modifying formulations for increased efficacy and targeted administration.

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:05/Issue:12/December-2023 Impact Factor- 7.868 www.irjmets.com

5. Clinical Trial Optimization: AI is being used to improve clinical trials, increase efficiency, and reduce costs. AI algorithms can help with patient enrollment, identifying acceptable trial demographics, and fine-tuning trial protocols.
6. Regulatory Compliance and Safety: AI is increasingly being used to ensure regulatory compliance and drug safety. AI algorithms can examine real-world data, reports of adverse events, and published literature to detect potential safety issues and monitor post-market medication safety.
7. Supply Chain Optimization: Artificial intelligence is being used to optimise pharmaceutical supply chains, assuring efficient manufacture, inventory control, and distribution. AI algorithms can estimate demand, optimise production schedules, and improve quality assurance methods, resulting in more efficient and cost-effective operations.

AI offers useful tools and approaches that can improve drug research and development processes. These organisations are using AI to analyse large datasets, forecast drug-target interactions, refine drug prospects, and simulate drug reactions inside biological systems. GNS Healthcare, AstraZeneca, Atomwise, Recursion Pharmaceuticals, and Insilico Medicines are a few examples.

PROGRESSIVE PERSPECTIVE

In the coming years, artificial intelligence has the potential to alter the pharmaceutical industry by speeding up medication research and development. Virtual screening approaches will rapidly scan large chemical libraries, identifying therapeutic candidates with the requisite properties and speeding up the discovery of lead compounds. The use of artificial intelligence in various aspects of healthcare is steadily increasing, spanning jobs ranging from triage to clinical risk assessment to diagnosis (Pokhriyal, Chavda, & Pathak, 2023) (Levin, et al., 2018). AI's clinical applications have the potential to improve diagnostic accuracy and streamline healthcare efficiency. Because of the significant resources involved in medicine research and development, more innovative approaches and strategies are required (Chen & Decary, 2020). Unfortunately, there are currently few practical uses of AI in medicine delivery, particularly in the therapeutic setting. Boost, k-nearest neighbours, decision trees, random forest, Nave Bayes, ANN, Feedback System Control (FSC), SVM, Set Covering Machine (SCM), and logistic regression are examples of AI techniques used in drug delivery for infectious disease management that have not received extensive evaluation or widespread adoption in clinical settings. This demonstrates the presence of considerable hurdles in the practical deployment of artificial intelligence for medicine delivery in the treatment of infectious diseases (Sun, Peng, Che, & Shukla, 2003) (Magill, et al., 2023). AI-powered models can forecast pharmacokinetic parameters, simulate drug dispersion and excretion in the body, and refine drug dose and administration methods.

VI. CONCLUSION

For the pharmaceutical sector, software has evolved into a critical instrument. Its incorporation has triggered a paradigm shift in operating procedures within businesses, resulting in significant improvements in productivity, efficiency, and precision. Software applications have revolutionised every aspect of the pharmaceutical value chain, from initial drug discovery and progression through clinical trials to maintaining regulatory compliance. Computational pharmaceutics, powered by AI and massive datasets, alters medicine delivery by providing a more effective, cost-efficient, and data-centric methodology. This promotes the improvement of medication formulations, personalised therapies, regulatory compliance, and risk minimization, ultimately leading in enhanced drug manufacturing processes and patient outcomes.

VII. REFERENCES

[1] Pharmaceutical Quality Management Software Market Size, Share & Trends Analysis Report By Application (Data Management, Risk Management), By Deployment Mode (Cloud & Web-based, On-premise), By Region, And Segment Forecasts, 2023 - 2030. San francisco U.S.: Grand view research.

[2] Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., & Najarian, K. (2021, January 18). Machine learning approaches and databases for prediction of drug-target interaction: a survey paper. briefing in Bioinformatics, 247-269.

[3] Balogh, G. T., Müller, J., & Könczöl, A. (2013). PH-Gradient PAMPA-Based in Vitro Model Assay for Drug-Induced Phospholipidosis in Early Stage of Drug Discovery. European Journal of Pharmaceutical Sciences, 81–89.

[4] BS, S., R, K., & N, A. (2008). Systematic optimisation of drug delivery systems: an insight. Pharmaceutical Review , 146-86.

[5] Cerón-Carrasco, D. J. (2022, June 21). ChemMedChem. Retrieved from Chemistry Europe: https://chemistryeurope.onlinelibrary.wiley.com/doi/full/10.1002/cmdc.202200278

[6] Cerón-Carrasco, D. J. (2022, June 21). When Virtual Screening Yields Inactive Drugs: Dealing with False Theoretical Friends. Retrieved June 27, 2023, from Chemistry Europe: https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/cmdc.202200278

[7] Chapman, A. B., Peterson, K. S., Alba, P. R., DuVall, S. L., & Patterson, O. V. (2019). Detecting Adverse Drug Events with Rapidly Trained Classification Models. Drug Safety, 147-156.

[8] Chavda, V. P., Vihol, D., Patel, A., & Redwan, E. M. (2023). Introduction to Bioinformatics, AI, and ML for Pharmaceuticals. In V. P. Chavda, D. Vihol, A. Patel, & E. M. Redwan, Bioinformatics Tools for Pharmaceutical Drug Product Development (pp. 1-18). John Wiley & Sons.

[9] Chen, M., & Decary, M. (2020, January). Artificial intelligence in healthcare: An essential guide for health leaders. Health care managment forum, 10-18.

[10] Colombo, S., Beck-Broichsitter, M., Bøtker, J. P., Malmsten, M., Rantanen, J., & Bohr, A. (2018, March 15). Transforming nanomedicine manufacturing toward Quality by Design and microfluidics. Adverse Drug Delivery Review, 115-131.

[11] Daka, A., & Peer, D. (2012). RNAi-based nanomedicines for targeted personalized therapy. Advanced drug delivery review, 1508-1521.

[12] Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2022). Machine Learning in Drug Discovery: A Review. Artificial Intelligence Review, 1947-1999.

[13] Das, P. J., Preuss, C., & Mazumder, B. (2016). Artificial Neural Network as Helping Tool for Drug Formulation and Drug Administration Strategies. Amsterdam, The Netherlands: Elsevier.

[14] Davenport, T., & Kalakota, R. (2019, January). The potential for artificial intelligence in healthcare. Future Healthcare Journal, 94-98.

[15] Dickherber, A., Morris, S. A., & Grodzinski, P. (2015, May- June). NCI investment in nanotechnology: achievements and challenges for the future. Wiley Interdiscip Rev Nanomed Nanobiotechnology, 251-265.

[16] Elkin, M. E., & Zhu, X. (2021, February 10). Predictive modeling of clinical trial terminations using feature engineering and embedding learning. Scientific Reports.

[17] Eslami, M., Adler, A., Caceres, R. S., Dunn, J. G., Kelley-Loughnane, N., Varaljay, V. A., et al. (2022, May). Artificial Intelligence for Synthetic Biology. Retrieved from Communications of the ACM: https://cacm.acm.org/magazines/2022/5/260341-artificial-intelligence-for-synthetic-biology/fulltext

[18] Goldstein, M., & Uchida, S. (2016, April 19). A Comparative Evaluation of Unsupervised Anomaly Detection Algorithms for Multivariate Data. Plos ONE.

[19] Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2019, November- December). The significance of artificial intelligence in drug delivery system design. Advanced Drug Delivery Review, 169-190.

[20] Hoffmann A, K.-S. J.-V. (1998). Computer system validation: an overview of official requirements and standards. Pharmaceutica acta Helvetiae, 317-325.

[21] Hole, G., Hole, A. S., & McFalone-Shaw, I. (2021). Digitalization in pharmaceutical industry: What to focus on under the digital implementation process? International Journal of Pharmaceutics: X.

[22] I, S., R, W., & IS, K. (2022). An experimental design in the optimization of various tablet excipient formulations- a concise review. nternational Journal of Applied Pharmaceutics, 28-32.

[23] Joshi, S. R., & Salunkhe, V. R. (2020). Overview on Software Used in Pharma Industry. International Journal of Pharmaceutical Science Review and Research, 52-58.

[24] Karim, M. R., Beyan, O., Zappa, A., Costa, I. G., Rebholz-Schuhmann, D., Cochez, M., et al. (2021, January). Deep learning-based clustering approaches for bioinformatics. Briefings in Bioinformatics, 22(1), 393–415.

[25] Kavasidis, i., Lallas, E., Gerogiannis, V. C., & Charitou, T. (2023, January). Predictive maintenance in pharmaceutical manufacturing lines using deep transformers. Procedia Computer Science, 576-583.

[26] Kelly, C. J., Karthikesalingam, A., Suleyman, M., Corrado, G., & King, D. (2019, October 29). Key challenges for delivering clinical impact with artificial intelligence. BMC Medicine.

[27] Kiseleva, A., Kotzinos, D., & Hert, P. D. (2022, May 30). Transparency of AI in Healthcare as a Multilayered System of Accountabilities: Between Legal Requirements and Technical Limitations. Frontiers Artificial Intelligence.

[28] Krikorian, G., & Torreele, E. (2021). We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis. Health Hum Rights, 119-127.

[29] Kumar, Y., Koul, A., Singla, R., & Ijaz, M. F. (2023). Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda. journal of Ambient intelligence and Humanized Computing, 8459-8486.

[30] Levin, S., Toerper, M., Hamrock, E., Hinson, J. S., Barnes, S., Gardner, H., et al. (2018, May). Machine-Learning-Based Electronic Triage More Accurately Differentiates Patients With Respect to Clinical Outcomes Compared With the Emergency Severity Index. Annals of emergency medicine, 565-574.

[31] Liu, L., Tang, L., Dong, W., Yao, S., & Zhou, W. (2016). An overview of topic modeling and its current applications in bioinformatics. SpringerPlus.

[32] Lou, H., Lian, B., & Hageman, M. J. (2021). Applications of Machine Learning in Solid Oral Dosage Form Development. Journal of Pharmaceutical Sciences, 3150-3165.

[33] Magill, E., Demartis, S., Gavini, E., Permana, A. D., Thakur, R. R., Adrianto, M. F., et al. (2023, August). Solid implantable devices for sustained drug delivery. Advance Drug Delivery Review, 2-31.

[34] Mak, K.-K., & Pichika, M. R. (2018, November 22). Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today, 773-780.

[35] Mali, P. Y. (2022). A review on worldwide essential software resources in pharmacy. Chronicles of Young Scientists, 11-20.

[36] Mannam, A., & Mubeen, H. (2018, May). Review Article Digitalisation And Automation In Pharmaceuticals From Drug Discovery To Drug Administration. International Journal of Pharmacy and Pharmaceutical Science, 1-10.

[37] Mohan, B., Kamaraj, R., & Navyaja, K. (2022). Role of Artificial Intelligence in Parenteral Formulation: A Review. Electrochemical Society Transactions, 20013-20020.

[38] Montgomery, D. C. (2019). Design and Analysis of Experiments (9 ed.). John Wiley & Sons.

[39] Munos, B. H. (2009). Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968. Nature Reviews Drug Discovery, 959-968.

[40] NNI Budget Supplements and Strategic Plans. (n.d.). (N. N. Office, Producer) Retrieved May 1, 2023, from National Nanotechnology Initiative:
https://www.nano.gov/NNIBudgetSupplementsandStrategicPlans

[41] Noguchi, Y., Ueno, A., Otsubo, M., Katsuno, H., Sugita, I., Kanematsu, Y., et al. (2018). A New Search Method Using Association Rule Mining for Drug-Drug Interaction Based on Spontaneous Report System. Frontiers in pharmacology, 197.

[42] Perincek, O., & Colak, M. (2013). Use of Experimental Box-Behnken Design for the Estimation of Interactions Between Harmonic Currents Produced by Single. Oguz Perincek, Metin Colak / International Journal of Engineering Research and Applications, 158-165.

[43] Pokhriyal, P., Chavda, V., & Pathak, M. (2023). Future Prospects and Challenges in the Implementation of AI and ML in Pharma Sector. In V. Chavda, K. Anand, & V. Apostolopoulos, BIOINFORMATICS TOOLS FOR PHARMACEUTICAL DRUG PRODUCT DEVELOPMENT (pp. 401-416). NJ, USA: Wiley: Hoboken.

[44] Puri, M., Pathak, Y., Sutariya, V. K., Tipparaju, S., & Moreno, W. (2015). Artificial Neural Network for Drug Design, Delivery and Disposition (1 ed.). Cambridge, MA, USA: Academic Press.

[45] R, J., & K, J. (2015). Review The Future of Pharmaceutical Manufacturing Sciences. Journal Of Pharmaceitical Sciences.

[46] Ramadhani, R. A., Riyadi, D. H., Triwibowo, B., & Kusumaningtyas, R. D. (2017). Review Pemanfaatan Design Expert untuk Optimasi Komposisi Campuran Minyak Nabati sebagai Bahan Baku Sintesis Biodiesel. Jurnal Teknik Kimia dan Lingkungan.

[47] S, B., & C., B. (2004). Pharmaceutical statistics: practical and clinical (4 ed.). New York: Marcel Dekker.

[48] Sarker, I. H. (2021, March 22). Machine Learning: Algorithms, Real-World Applications and Research Directions. Springer Link.

[49] Sarker, I. H. (2022, February 10). AI-Based Modeling: Techniques, Applications and Research Issues Towards Automation, Intelligent and Smart Systems. SpringerLink.

[50] Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012, March 1). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Review, drug discovery, 191-200.

[51] Shah, H., Chavda, V., & Soniwala, M. M. (2023). Applications of Bioinformatics Tools in Medicinal Biology and Biotechnology. In V. Chavda, K. Anand, & V. Apostolopoulos, Bioinformatics Tools for Pharmaceutical Drug Product Development (pp. 95-116). Nj, USA: Wiley: Hoboken.

[52] Sun, Y., Peng, Y., Che, Y., & Shukla, A. J. (2003). Application of artificial neural networks in the design of controlled release drug delivery systems. Advanced drug delivery review, 1201-1215.

[53] Thomas, S., Abraham, A., Baldwin, J., Piplani, S., & Petrovsky, N. (2021). Artificial Intelligence in Vaccine and Drug Design. In S. Thomas, A. Abraham, J. Baldwin, S. Piplani, & N. Petrovsky, Vaccine Design (pp. 131-146).

[54] Troiano, G., Nolan, J., Parsons, D., Hoven, C. V., & Zale, S. (2016). A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products. American Association of Pharmaceutical Scientists (AAPS), 1354-1365.

[55] Turchin, A., Masharsky, S., & Zitnik, M. (2023). Comparison of BERT implementations for natural language processing of narrative medical documents. Informatics in Medicine Unlocked, 1-7.

[56] Upadhyay, P. (2012). The Role of "Verification and Validation in System Development Life Cycle''. IOSR Journal of Computer Engineering, 17-20.

[57] Usman, S., Ejaz, R. R., & Safdar, K. (2018). Formulation development and optimization of orally disintegrating tablets of montelukast sodium by Design- Expert. Tropical Journal of Pharmaceutical Research, 1701.

[58] Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., et al. (2019). Applications of machine learning in drug discovery and development. Nat Review Drug Discovery, 463-477.

[59] Vyas, M., Thakur, S., Riyaz, B., Bansal, K., Tomar, B., & Mishra, V. (2018, April). Artificial intelligence: The beginning of a new era in pharmacy profession. Asian Journal of Pharmaceutics, 72-76.

[60] Zhao, W., Chen, J. J., Perkins, R., Liu, Z., Ge, W., Ding, Y., et al. (S8 (2015)). A heuristic approach to determine an appropriate number of topics in topic modeling. BMC Bioinformatics, 16.